Acadia Pharma drug fails to improve psychosis in schizophrenia patients
A plan to expand the use of Acadia Pharmaceuticals’ only approved medicine to cover the treatment of patients with schizophrenia was dealt a setback on Monday with the failure of a late-stage clinical trial, the company said.
The Acadia drug, called Nuplazid, failed to improve the overall symptoms of schizophrenia compared with a placebo. The Phase 3 study enrolled nearly 400 schizophrenia patients with moderate to severe psychotic symptoms inadequately controlled by currently approved drugs.
Read Original Article: Acadia Pharma drug fails to improve psychosis in schizophrenia patients »
